Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.
Saved in:
| Title: | Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma. |
|---|---|
| Authors: | Lee V; Department of Ophthalmology and Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia., Hultcrantz M; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York., Petrone S; GSK, New Hope, Pennsylvania., Lewis EW; GSK, Durham, North Carolina., Banna H; Department of Ophthalmology, University of North Carolina at Chapel Hill., Lichtman E; Division of Hematology, University of North Carolina at Chapel Hill., Thulasi P; Emory University, Atlanta, Georgia.; Now with Ophthalmology and Visual Sciences Division of Cornea and External Disease, Washington University Physicians, St Louis, Missouri., Quick AA; Department of Ophthalmology, University of Kansas Medical Center, Prairie Village., Jeng BH; Ophthalmology and Visual Sciences, University of Maryland, Baltimore.; Now with Department of Ophthalmology and Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia., Sunshine SB; Ophthalmology and Visual Sciences, University of Maryland, Baltimore., Francis JH; Ophthalmic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Canestraro J; Ophthalmic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Farooq AV; Department of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois., Clements P; Pathology, Nonclinical Safety, GSK, Stevenage, United Kingdom., Robertson N; Nonclinical Safety, GSK, Stevenage, United Kingdom., Burman M; Formerly with Department of Genetic Toxicology, GSK, Ware, United Kingdom., McKevitt T; Pathology, Nonclinical Safety, GSK, Stevenage, United Kingdom.; Now with Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, United Kingdom., Struemper H; Clinical Pharmacology Modeling & Simulation, GSK, Durham, North Carolina., Weir L; Nonclinical Safety, GSK, Stevenage, United Kingdom. |
| Source: | JAMA ophthalmology [JAMA Ophthalmol] 2025 Jun 01; Vol. 143 (6), pp. 507-514. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print Cited Medium: Internet ISSN: 2168-6173 (Electronic) Linking ISSN: 21686165 NLM ISO Abbreviation: JAMA Ophthalmol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6173 |
|---|---|
| DOI: | 10.1001/jamaophthalmol.2025.1008 |
